| Name | empagliflozin |
|---|---|
| Synonyms |
Glyxambi
BI-10773;BI 10773;BI Englizin Empagliflozin, 10 mM in DMSO Engeleijing BI-10773 EMpagliflozin Empagliflozin CAS NO.864-0 (1S)-1,5-Anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydro-3-furanyloxy]benzyl}phenyl)-D-glucitol Empaglilozin (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Empagliflozin 13C6 CE0108 (2S,3R,4R,5S,6R)-Chloro-(3S)-tetrahydrofuran-3-yloxyphenylmethylphenyl-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol Empagliflozin Empagli ozin (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI X5927 Empag Ipagliflozin Jardiance AJ93046 3-Piperidinecboxylicacid,1-methoxy-10-oxo-,methylester Empagliflozin //BP CS0940 Empagliflozin,inhibit,Inhibitor,SGLT,BI-10773,Sodium-dendent glucose cotransporters,BI10773 EmpagL High purity CAS 129-1 Dapoxetine hcl CAS NO.864-0 Empagliflozin API alegin EMPAGLIFLBZIN Empagliflozin(W.S) Empagliflozin whatsapp BI10773 (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin crystalline Boehringer Ingelheim(BI-44847) D4-(S)-Empagliflozin ozin 2H-1,4-Benzoxazine-7-cboxylicacid,3,10-dihydro-,methylester (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol Empagliflozin Impurity A (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol Empaglifloin PB23119 D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S) mpagliflozin Empagliflflozin CS-0940 Empagliflozin,min EMpagliflozin/ BI-10773 (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[4-[[(S)-3-tetrahydrofuranyl]oxy]benzyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol (1S)-1,5-Anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol Empagliflozin D4Q: What is Empagliflozin D4 Q: What is the CAS Number of Empagliflozin D4 Q: What is the storage condition of Empagliflozin D4 Q: What e the applications of Empagliflozin D4 Englejin Empagliflozin(BI10773,VA10802) VA10802 |
| Description | Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2. |
|---|---|
| Related Catalog | |
| Target |
IC50: 3.1 nM (SGLT-2), 1.1 μM (SGLT-5), 2 μM (SGLT-6), 8.3 μM (SGLT-1), 11 μM (SGLT-4)[1] |
| In Vitro | Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin inhibits the uptake of [14C]-alpha-methyl glucopyranoside (AMG) via hSGLT-2 in a dose-dependent manner with an IC50 of 3.1 nM, but is less potent for other SGLTs (IC50 range: 1100-11000 nM). [3H]-Empagliflozin displays a high affinity for SGLT-2 with a mean Kd of 57±37 nM in the absence of glucose in kinetic binding experiments[1]. |
| In Vivo | Glucose intolerance is significantly improved after 8 days of Empagliflozin treatment at either dose (3mg/kg Empagliflozin 3058±180 vs 10mg/kg Empagliflozin 3090±219). Therefore, acute treatment with Empagliflozin has a beneficial effect on hyperglycemia and glucose intolerance. Since there are no significant differences in blood glucose homeostasis with the two different doses of Empagliflozin, and random blood glucose levels of T1DM mice are significantly improved by 3mg/kg of Empagliflozin, the effect of the lower dose of Empagliflozin (3mg/kg) is investigated on preserving β-cell mass and function[2]. |
| Kinase Assay | Membranes (60 μg/well) are assayed in a 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) containing 137 mM NaCl in the presence or absence of 20 mM glucose and indicated concentrations of [3H]-Empagliflozin in 96-well plates at room temperature for 2 h. Incubations are stopped by rapid filtration through GF/B Filterplates impregnated with polyethyleneimine 0.5% and prewetted with 0.9% NaCl solution, and washed four times with 0.9% NaCl solution (4°C) using a Harvester Filtermate 96. Filterplates are dried for 2 h and 50 μL of Microscint 20 is added to each well. Radioactivity retained on the filters is measured using the TopCount NXT. In parallel, the actual amount of activity used in the assays is determined by adding the same amount of [3H]-Empagliflozin that is added per well in the radioligand binding studies and 4 mL Ultima Gold Scintilator into 5 mL vials and measuring using a Tricarb 2900TR. Non-specific [3H]-Empagliflozin-binding is determined in the presence of 30 μM dapagliflozin[1]. |
| Animal Admin | Mice[2] Male C57BL/6J mice (10 weeks of age) are used. Empagliflozin is dissolved in hydroxy ethyl cellulose (HEC) and administered to mice in the experimental group (3 or 10 mg/kg) by oral gavage once daily for 8 days, whereas the vehicle group is given same volume of HEC alone. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 664.5±55.0 °C at 760 mmHg |
| Molecular Formula | C23H27ClO7 |
| Molecular Weight | 450.909 |
| Flash Point | 355.7±31.5 °C |
| Exact Mass | 450.144531 |
| PSA | 108.61000 |
| LogP | 3.38 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.628 |
|
~74%
864070-44-0 |
| Literature: BOEHRINGER INGELHEIM INTERNATIONAL GMBH; WEBER, Dirk; RENNER, Svenja; FIEDLER, Tobias; ORLICH, Simone Patent: WO2011/39107 A1, 2011 ; Location in patent: Page/Page column 21-23 ; |
|
~74%
864070-44-0 |
| Literature: BOEHRINGER INGELHEIM INTERNATIONAL GMBH Patent: US2011/237526 A1, 2011 ; Location in patent: Page/Page column 8 ; |
|
~%
864070-44-0 |
| Literature: US2006/258749 A1, ; Page/Page column 29-30 ; |
|
~%
864070-44-0 |
| Literature: US2011/237789 A1, ; |
|
~%
864070-44-0 |
| Literature: US2011/237789 A1, ; |
|
~%
864070-44-0 |
| Literature: US2011/237789 A1, ; |
|
~%
864070-44-0 |
| Literature: US2011/237789 A1, ; |
| Precursor 7 | |
|---|---|
| DownStream 0 | |